Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
AnGes to Roll Out Progeria Treatment Zokinvy on May 27
AnGes said on May 23 that it will launch its progeria treatment Zokinvy (lonafarnib) in Japan on May 27.The drug was approved in January and joined the NHI price list in April for the indication of Hutchinson-Gilford-Progeria syndrome and processing-deficient…
To read the full story
Related Article
BUSINESS
- Ferring’s Adstiladrin, Boehringer’s Jascayd Hit Market; Haizexin Due July 28
July 16, 2026
- JCR to File DMD Drug Givinostat in Japan by End-2026
July 16, 2026
- FRONTEO, Daiichi Sankyo Build AI Model to Analyze Toxicity Reports
July 15, 2026
- Cell Resources Launches Umbilical Cord- and Amnion-Derived MSCs
July 15, 2026
- iPark Eyes Shared AI Platform to Keep Japan in Global Drug Discovery Race
July 14, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…